FDA Warning Letter – MyRXCash

Leave a comment
TO:         MyRXCash
 

FROM: The United States Food and Drug Administration

RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to
               United States Consumers over the Internet
DATE:  September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
For example, your websites offer tramadol, marketed as “tramadol 50 mg/ml,” described as an “immediate-release oral formulation” that is “used to treat pain and discomfort ranging from mild to severe cases….” While there are FDA-approved versions of tramadol in tablet and capsule form on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the “tramadol 50 mg/ml” oral solution product marketed on your websites. FDA-approved tramadol bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses risks including addiction, abuse, misuse, life-threatening respiratory depression (breathing problems), and neonatal opioid withdrawal syndrome (withdrawal symptoms in newborn baby). In addition, when taken in conjunction with other central nervous system depressants, including alcohol, use may result in coma or death.
Misbranded Drugs
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drug is a prescription product intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use this product safely for its intended use(s). Consequently, the labeling for this product fails to bear adequate directions for its intended use(s), causing it to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)].  Because “tramadol 50 mg/ml” is not approved in the U.S., it is also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
Offering tramadol for sale on your websites is particularly concerning given its potential for abuse and dependency, especially amid the growing epidemic of opioid abuse in the U.S.  The Centers for Disease Control and Prevention found that opioid overdose deaths involving prescription opioids have quadrupled since 1999, and in 2015, opioids were involved in the deaths of 33,091 people in the U.S.[1] In addition, deaths by drug overdose, including overdose from prescription opioids, are now the leading cause of injury death in the U.S.\
* * *
FDA is taking this action against MyRXCash because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products that you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
  
 
Table of Websites:
Connecting URL
 
directpharmas.net
nextdaycheckout.com
buypropeciashop.net
rx-checkout.net
buyimovane.com
buysonataonline.com
buyzaleplononline.com
buyzopicloneonline.com
canadapillstore.com
canadatabs.com
drugs-medstore.com
drugs-ship.com
rx-rev.com
trusts-rx.com
24×7-pillstore.net
buylunestaonline.net
cadrugstore.net
canadatabs.net
canadianmedstore.net
canadianpillstore.net
directspharma.com
Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

 

[1] Drug Overdose Death Data, Centers for Disease Control and Prevention, athttps://www.cdc.gov/drugoverdose/data/statedeaths.html [Accessed August 28, 2017].

FDA Warning Letter – MediPK

Leave a comment

TO: MediPK

FROM: The United States Food and Drug Administration

RE: Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to
United States Consumers over the Internet

DATE: September 19, 2017
WARNING LETTER

The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.

Unapproved New Drugs

As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].

For example, your websites offer unapproved new drugs such as tramadol, marketed as “Tonoflex SR” and described as “a medication used to treat pain that is moderate to severe.” While there are FDA-approved versions of tramadol on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the “Tonoflex SR” product marketed on your websites. FDA-approved tramadol bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses risks including addiction, abuse, misuse, life-threatening respiratory depression (breathing problems), and neonatal opioid withdrawal syndrome (withdrawal symptoms in newborn baby). In addition, when taken in conjunction with other central nervous system depressants, including alcohol, use may result in coma or death.

Your websites also offer for sale unapproved codeine products such as “Brufen Plus+” which is described on the image of the label on your websites as containing codeine and ibuprofen and “Powerful Double Action for Pain Relief.” While there are FDA-approved codeine products on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the “Brufen Plus+” product marketed on your websites. There are also no approved drug applications in the U.S. for products that contain the combination of codeine and ibuprofen. FDA-approved codeine bears a boxed warning that addresses risks including addiction, abuse, misuse, life-threatening respiratory depression, and neonatal opioid withdrawal syndrome. In addition, when taken in conjunction with other central nervous system depressants, including alcohol, use may result in coma or death.

Misbranded Drugs

A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.

Because the aforementioned drugs are prescription products intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use these products safely for their intended use(s). Consequently, the labeling for these products fails to bear adequate directions for their intended use(s), causing them to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].

Offering these drugs for sale on your websites is particularly concerning given their potential for abuse and dependency, especially amid the the growing epidemic of opioid abuse in the U.S. The Centers for Disease Control and Prevention found that opioid overdose deaths involving prescription opioids have quadrupled since 1999, and in 2015, opioids were involved in the deaths of 33,091 people in the U.S.[1] In addition, deaths by drug overdose, including overdose from prescription opioids, are now the leading cause of injury death in the U.S.

* * *
FDA is taking this action against MediPK because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.

This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products that you market are in compliance with the FD&C Act and its implementing regulations. You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above). Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.

Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.

If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.

Table of Websites:
Connecting URL

clinixplus.com
ourezee.com
chemicalsupplyltd.net
clinixplus.net
ahpharmacy.com
clinixmass.com
healthdrugsforu.com
jaishaenterprises.com
lookandtook.com
mallofmedicine.com
medicomedicine.com
pharmaplusplus.com
anabolicneeds.net
clinixmass.net
mallofmedicine.net
medicomedicine.net
medipk.com
hexameds.com
meds5.com
steroidxone.com
medi-pk.com
pakonlinepharmacy.com
thepharmacyplus.com
zafaxpharma.com
247plus.net

Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

[1] Drug Overdose Death Data, Centers for Disease Control and Prevention, at https://www.cdc.gov/drugoverdose/data/statedeaths.html [Accessed August 28, 2017].
2017
Page Last Updated: 09/19/2017

FDA Warning Letter – Medicina Mexico

Leave a comment
TO:        Medicina Mexico
FROM:  The United States Food and Drug Administration
RE:         Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet
DATE:  September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 331(k), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)].  No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
An example of an unapproved new drug on your websites is chloranfenicol (also known as chloramphenicol) offered for sale under the brand name, Lebrocetin. Your websites claim that chloranfenicol is an “antibiotic indicated for typhoid, paratyphoid, rickettsial, brucellosis, meningitis, endocarditis, osteomyelitis, bacteremia and infections caused by anaerobic bacteria.” There are currently no approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for oral chloramphenicol.  On September 21, 2016, it was announced in the Federal Register that FDA would not accept or approve abbreviated new drug applications (ANDAs) for chloramphenicol capsules, 50 mg, 100 mg, 250 mg, or chloramphenicol palmitate oral suspension, 150 mg/5 mL because previously approved versions of these chloramphenicol products were determined to have been withdrawn from sale in the U.S. for reasons of safety or effectiveness. (81 FR 64914)
Prior to being removed from the market, the approved labeling for these products contained a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating the drug carries a significant risk of serious or life-threatening adverse effects. The boxed warning for chloramphenicol indicated that serious and sometimes fatal blood disorders [e.g., hypoplastic or aplastic anemia (very few or no blood cells in bone marrow), thrombocytopenia (low blood platelet counts), and granulocytopenia (low white blood cell counts)] are known to occur after administration of chloramphenicol. The boxed warning further described aplastic anemia attributed to chloramphenicol that later resulted in leukemia. In determining that these products had been withdrawn for reasons of safety and effectiveness, FDA relied on the fact that additional therapies with less severe adverse drug effects have been approved, and that, therefore, the risks associated with these chloramphenicol products as labeled outweighed the benefits.
Misbranded Drugs
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s).  “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drugs are prescription products intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use(s).  Consequently, the labeling for these products fails to bear adequate directions for their intended use(s), causing them to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)].  Because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
Your websites also offer prescription drugs for sale without a prescription.  Prescription products, as defined in the FD&C Act § 503(b)(1) include those that, because of their toxicity or other potentiality for harmful effect, and/or the method of their use, and/or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. For example, both chloramphenicol and Levaquin (levofloxacin) are prescription drug products as defined in the FD&C Act § 503(b)(1) that are offered for sale on your websites without a prescription. Chloramphenicol is associated with serious risks including, but not limited to, fatal aplastic anemia and the approved labeling for this product, before it was withdrawn from sale, recommended extensive safety monitoring, including baseline blood studies followed by periodic blood studies approximately every 2 days.
Levaquin is the brand name of a prescription drug approved by FDA to treat certain bacterial infections. The labeling for the FDA-approved Levaquin product contains a boxed warning that addresses serious adverse reactions including tendinitis (tendon rupture or swelling of the tendon), peripheral neuropathy (changes in sensation and possible nerve damage), central nervous system effects (e.g., convulsions, dizziness, lightheadedness, increased intracranial pressure), and exacerbation of myasthenia gravis (a chronic disease that causes muscle weakness).
Under U.S. law, prescription drug products can be dispensed only pursuant to a prescription from a healthcare practitioner licensed by law to administer prescription drugs. Your offering prescription drug products without requiring a prescription jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. Dispensing a prescription drug without a valid prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].
* * *
FDA is taking this action against Medicina Mexico because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs.  Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law.  It is your responsibility to ensure that all products you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed.  Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
Table of Websites:
Connecting URL
 
americanonlinepharmacy.com
buymeds4less.com
buymedsonlinenow.net
buyrxmedsnow.com
meds4sale.com
orderyourmedsonline.com
rxmexicoonline.com
rxonline.com.mx
Sincerely,
/s/
Thomas Christ
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

FDA Warning Letter – HA Stores, Ltd

Leave a comment
TO:         HA Stores, Ltd
 
FROM: The United States Food and Drug Administration

RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to
               United States Consumers over the Internet
DATE:  September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
For example, your websites offer for sale Roxicodone, marketed as “Roxicontin” and described as a “narcotic pain reliever that shows its magical response by producing the calming effect” and is used “in the treatment of chronic pain that is moderate to severe.” While there are FDA-approved versions of Roxicodone on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the “Roxicontin” product marketed on your websites.  FDA-approved Roxicodone bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses risks including addiction, abuse, misuse, life-threatening respiratory depression (breathing problems), and neonatal opioid withdrawal syndrome (withdrawal symptoms in newborn baby). In addition, when taken in conjunction with other central nervous system depressants, including alcohol, use may result in coma or death.
Your websites also offer for sale “Slimall (Meridia)” marketed as a “medicine used to treat obesity.”   “Slimall (Meridia)” is an unapproved drug because there are currently no FDA-approved applications in effect for this product. Although Meridia was approved for use in the U.S. in 1997 for weight loss and maintenance of weight loss in obese people, it was voluntarily withdrawn from the U.S. market in December 2010, due to clinical trial data indicating an increased risk of heart attack and stroke.[1]  In an FDA Safety Alert in October 2010, the Agency recommended that physicians stop prescribing Meridia to their patients and for patients to stop taking this medication due to severe adverse events associated with use of the product.
Misbranded Drugs
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drugs are prescription products intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use these products safely for their intended use(s). Consequently, the labeling for these products fails to bear adequate directions for their intended use(s), causing them to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)].  Because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
Offering Roxicodone for sale on your websites is particularly concerning given its potential for abuse and dependency, especially amid the growing epidemic of opioid abuse in the U.S.  The Centers for Disease Control and Prevention found that opioid overdose deaths involving prescription opioids have quadrupled since 1999, and in 2015, opioids were involved in the deaths of 33,091 people in the U.S.[2]  In addition,  deaths by drug overdose, including overdose from prescription opioids, are now the leading cause of injury death in the U.S.
* * *
FDA is taking this action against HA Stores, Ltd because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products that you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
Table of Websites:
Connecting URL
 
healthymedz.com.ru
yjflooring.com
rx-easymeds.com
easy-medico.com
controlledmeds.com
healthyzstorez.com
uk-drugs.com
drug-cart.com
rx-medico.com
beabons.com
chlok.com
cis188.com
granuu.com
inhousepharmacy24.com
nj-xany.com
qalwa.com
shengyangjingpin.com
melsembler.com
rx-easymedz.com
rxmedico.com
weight-loss-medicine.com
Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration
 

[1] Withdrawal of Approval of a New Drug Application for Meridia, 75 Fed. Reg. 80061(Dec. 21, 2010).http://www.gpo.gov/fdsys/pkg/FR-2010-12-21/pdf/2010-31986.pdf [Accessed July 24, 2017]
[2] Drug Overdose Death Data, Centers for Disease Control and Prevention, athttps://www.cdc.gov/drugoverdose/data/statedeaths.html [Accessed August 28, 2017].

FDA Warning Letter – GlavMed

Leave a comment
TO:       GlavMed
FROM: The United States Food and Drug Administration
RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet
DATE:  September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 331(k), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses.  New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)].  No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products.  Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
An example of an unapproved new drug on your websites is oral chloramphenicol. Your websites claim that chloramphenicol “is used for treating serious infections caused by certain bacteria.” There are currently no approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for oral chloramphenicol.  On September 21, 2016, it was announced in the Federal Register that FDA would not accept or approve abbreviated new drug applications (ANDAs) for chloramphenicol capsules, 50 mg, 100 mg, 250 mg, or chloramphenicol palmitate oral suspension, 150 mg/5 mL because FDA determined that  previously approved versions of these chloramphenicol products were withdrawn from sale in the U.S. for reasons of safety or effectiveness. (81 FR 64914)
Prior to their removal from the market, the approved labeling for these products contained a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating the drug carries a significant risk of serious or life-threatening adverse effects. The boxed warning for chloramphenicol indicated that serious and sometimes fatal blood disorders [e.g., hypoplastic or aplastic anemia (very few or no blood cells in bone marrow), thrombocytopenia (low blood platelet counts), and granulocytopenia (low white blood cell counts)] are known to occur after administration of chloramphenicol. The boxed warning further described aplastic anemia attributed to chloramphenicol that later resulted in leukemia. In determining that these products had been withdrawn for reasons of safety and effectiveness, FDA relied on the fact that additional therapies with less severe adverse drug effects have been approved, and reasoned that the risks associated with these chloramphenicol products as labeled therefore outweighed the benefits.
Another example of an unapproved new drug product offered on your websites is roxithromycin, which your websites claim is “used for treating several different infections, including some STDs, upper and lower respiratory tract infections and asthma, gum infections like gingivitis, and bacterial infections associated with stomach and intestinal ulcers.”  There are currently no (and have never been) approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for roxithromycin in the U.S.
Misbranded Drugs
Your websites also offer prescription drugs for sale without a prescription.  Prescription products, as defined in the FD&C Act § 503(b)(1) include those that, because of their toxicity or other potentiality for harmful effect, and/or the method of their use, and/or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. For example, both of the drugs identified above (chloramphenicol and roxithromycin) are prescription drugs as defined in the FD&C Act § 503(b)(1) and are offered on your websites for sale without a prescription. Chloramphenicol is associated with serious risks including, but not limited to, fatal aplastic anemia, and the approved labeling for this product, before it was withdrawn from sale, recommended extensive safety monitoring, including baseline blood studies followed by periodic blood studies approximately every 2 days.
Under U.S. law, prescription drug products can be dispensed only pursuant to a prescription from a healthcare practitioner licensed by law to administer prescription drugs. Your offering prescription drug products without requiring a prescription jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. Dispensing a prescription drug without a valid prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s).  “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drugs are prescription products intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the products safely for their intended use(s).  Consequently, the labeling for these products fails to bear adequate directions for their intended use(s), causing them to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
* * *
FDA is taking this action against GlavMed because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs.  Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law.  It is your responsibility to ensure that all products you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
Table of Websites:
Connecting URL
reynoldsdrug.com
cipropharmacy.com
rxmedscanada.com
internationalpharm.net
official-drugstore.com
med-shop365.com
meds-247.com
topmedsonline24-7.com
trustmdeal.com
vipmdline.com
soikin.com
canadianqualitydrugs.net
med-shop24.net
secureonline-shop.com
buy-azithromycin.top
online-ph.com
drugsforhealth.org
rx-canadian-store.com
amoxil-news.net
mypills24x7.com
buyamoxicillinnorx.com
buyazithromycinnorx.com
buymetronidazolenorx.com
medcareonline.net
canadianmed.net
pharmacygen.com
topdrugstore24.com
yourcanadianmeds.com
world-medstore.com

Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

FDA Warning Letter – Bulk2USA

Leave a comment
TO:         Bulk2USA
 
RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet
DATE: September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 331(k), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
For example, your websites offer unapproved new drugs, including hydrocodone and acetaminophen 10/500 mg, which is described as a “combination of narcotic drug (Hydrocodone) and non narcotic drug (Acetaminophen)…. used to treat Moderate to severe pain.” While there are FDA-approved versions of hydrocodone and acetaminophen on the market in the U.S., there are currently no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the hydrocodone products that contain 500 mg of acetaminophen offered for sale on your websites. In January 2011, due to the risk of severe liver injury, FDA issued a Drug Safety Communication and asked drug manufacturers to voluntarily limit the strength of acetaminophen in prescription drugs to 325 mg per tablet or capsule to make these products safer for patients. FDA announced via a Federal Register notice its intention to intitiate withdrawal proceedings pursuant to section 505(e)(2) of the FD&C Act for any prescription acetaminophen combination products with acetaminophen strengths greater than 325 mg still on the market as of January 2014.[1]which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses risks including, addiction, abuse, misuse, life-threatening respiratory depression (breathing problems), neonatal opioid withdrawal syndrome (withdrawal symptoms in newborn baby), and hepatotoxicity (liver failure). In March 2014, FDA announced the withdrawal of 108 abbreviated new drug applications (ANDA) for prescription pain drug products containing more than 325 mg of acetaminophen.[2] In addition, FDA-approved hydrocodone and acetaminophen also bears a boxed warning, commonly referred to as a “black box warning,”
Your websites also offer for sale tramadol, marketed as “Tramal SR,” and described as an “opioid pain medication… to treat moderate to moderately severe pain.” While there are FDA-approved versions of tramadol on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the “Tramal SR” product marketed on your website.  FDA-approved tramadol bears a boxed warning addressing risks including addiction, abuse, misuse, life-threatening respiratory depression, and neonatal opioid withdrawal syndrome. In addition, when taken in conjunction with other central nervous system depressants, including alcohol, use may result in coma or death.
Misbranded Drugs
Your websites also offer for sale prescription drugs without a prescription. Prescription products, as defined in FD&C Act § 503(b)(1) include those that, because of their toxicity or other potentiality for harmful effect, and/or the method of their use, and/or the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs offered for sale on your website include opioids such as tramadol and hydrocodone drug products. Offering these drugs for sale on your websites is particularly concerning given potential for abuse and dependency, especially amid the growing epidemic of opioid abuse in the U.S. The Centers for Disease Control and Prevention found that opioid overdose deaths involving prescription opioids have quadrupled since 1999, and in 2015, opioids were involved in the deaths of 33,091 people in the U.S.[3]  In addition, deaths by drug overdose, including overdose from prescription opioids, are now the leading cause of injury death in the U.S.
Under U.S. law, prescription drug products can be dispensed only pursuant to a prescription from a healthcare practitioner licensed by law to administer prescription drugs.  Your offering prescription drug products without requiring a prescription jeopardizes patient safety and misbrands the drug products under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].
In addition, a drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drugs are prescription products intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use these products safely for their intended use(s). Consequently, the labeling for these products fails to bear adequate directions for their intended use(s), causing them to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering these drugs for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
* * *
FDA is taking this action against Bulk2USA because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products that you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
Table of Websites:
Connecting URL
 
buyrx-online.com
medscareonline.com
silkroadmeds.com
drugs-order.net
cureonlinepharmacy.net
buy-rxonline.net
deluxepharmacy.net
drugsplace.com
us2us-rx.com
onlinerxhub.com
onlineuspharma.com
rxpharmacyline.com
Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

 

[1] Prescription Drug Products Containing Acetaminophen: Actions to Reduce Liver Injury from Unintentional Overdose, FDA-2011—N-0021, January 14, 2011.
[2]Actavis Totowa LLC, et al.; Withdrawal of Approval of Abbreviated New Drug Applications for Prescription Pain Medications Containing More Than 325 Milligrams of Acetaminophen, FDA-2011-N-0021,https://www.federalregister.gov/documents/2014/03/27/2014-06801/actavis-totowa-llc-et-al-withdrawal-of-approval-of-abbreviated-new-drug-applications-for, March 27, 2014. 
[3] Drug Overdose Death Data, Centers for Disease Control and Prevention, athttps://www.cdc.gov/drugoverdose/data/statedeaths.html [Accessed August 28, 2017].

FDA Warning Letter – American Pharmacy Group

Leave a comment
TO:         American Pharmacy Group
 
FROM: The United States Food and Drug Administration

RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet
DATE: September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
For example, your websites offer unapproved new drugs including, hydrocodone and acetaminophen 10/500 mg, marketed as “combined to achieve pain relief.” While there are FDA-approved versions of hydrocodone and acetaminophen on the market in the U.S., there are currently no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the hydrocodone products that contain 500 mg of acetaminophen offered for sale on your websites. In January 2011, due to the risk of severe liver injury, FDA issued a Drug Safety Communication and asked drug manufacturers to voluntarily limit the strength of acetaminophen in prescription drugs to 325 mg per tablet or capsule to make these products safer for patients.  Also in January 2011, FDA announced via a Federal Register notice its intention to intitiate withdrawal proceedings pursuant to section 505(e)(2) of the FD&C Act for any prescription acetaminophen combination products with acetaminophen strengths greater than 325 mg still on the market as of January 2014.[1] In March 2014, FDA announced the withdrawal of 108 abbreviated new drug applications (ANDA) for prescription pain drug products containing more than 325 mg of acetaminophen.[2] In addition, FDA-approved hydrocodone and acetaminophen also bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses risks including addiction, abuse, misuse, life-threatening respiratory depression (breathing problems), neonatal opioid withdrawal syndrome (withdrawal symptoms in newborn baby), and hepatotoxicity (liver failure).
Misbranded Drugs
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drug is a prescription product intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use this product safely for its intended use(s). Consequently, the labeling for this product fails to bear adequate directions for its intended use(s), causing it to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because hydrocodone and acetaminophen 10/500 mg is not approved in the U.S., it is also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
Offering hydrocodone products for sale on your websites is particularly concerning given the potential for abuse and dependency, especially amid the growing epidemic of opioid abuse in the U.S. The Centers for Disease Control and Prevention found that opioid overdose deaths involving prescription opioids have quadrupled since 1999, and in 2015, opioids were involved in the deaths of 33,091 people in the U.S.[3]  In addition, deaths by drug overdose, including overdose from prescription opioids, are now the leading cause of injury death in the U.S.
* * *
FDA is taking this action against American Pharmacy Group because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products that you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
 
Table of Websites:
Connecting URL
 
rxgreenovernight247.net
discreetdelivery.net
mrpharmacy.net
rxclick1.com
rxforever.com
rxplaces.com
rxclick1.net
rxforever.net
rxplaces.net
hi2rx.com
rx3go.com
sky2med.com
usabigstores.com
hi2rx.net
rx3go.net
safeshopping1.net
sky2med.net
storerx.net
rxcoinshealthcare247.net
blueovernight.com
safeshopping1.com
Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

[1] Prescription Drug Products Containing Acetaminophen: Actions to Reduce Liver Injury from Unintentional Overdose, FDA-2011-N-0021, January 14, 2011.
[2]Actavis Totowa LLC, et al.; Withdrawal of Approval of Abbreviated New Drug Applications for Prescription Pain Medications Containing More Than 325 Milligrams of Acetaminophen, FDA-2011-N-0021,https://www.federalregister.gov/documents/2014/03/27/2014-06801/actavis-totowa-llc-et-al-withdrawal-of-approval-of-abbreviated-new-drug-applications-for, March 27, 2014. 
[3] Drug Overdose Death Data, Centers for Disease Control and Prevention, athttps://www.cdc.gov/drugoverdose/data/statedeaths.html [Accessed August 31, 2017].

FDA Warning Letter – 247Med.com

Leave a comment
10903 New Hampshire Avenue
Silver Spring, MD 20993
TO:         247Med
 
FROM: The United States Food and Drug Administration

RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet
DATE: September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
For example, your websites offer unapproved new drugs such as, tramadol, marketed as “Tramadol retard” and described as an “analgesic” that is “indicated to treat moderate to severe pain.” While there are FDA-approved versions of tramadol on the market in the U.S., there are no approved drug applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for the “Tramadol retard” product marketed on your websites.  FDA-approved tramadol bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses risks including addiction, abuse, misuse, life-threatening respiratory depression (breathing problems), and neonatal opioid withdrawal syndrome (withdrawal symptoms in newborn baby).  In addition, when taken in conjunction with other central nervous system depressants, including alcohol, use may result in coma or death.
Misbranded Drugs
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Because the aforementioned drug is a prescription product intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for its intended use(s). Consequently, the labeling for this product fails to bear adequate directions for its  intended use(s), causing it to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because “Tramadol retard” is not approved in the U.S., it is also not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
Offering tramadol for sale on your websites is particularly concerning given its potential for abuse and dependency, especially amid the growing epidemic of opioid abuse in the U.S.  The Centers for Disease Control and Prevention found that opioid overdose deaths involving prescription opioids have quadrupled since 1999, and in 2015, opioids were involved in the deaths of 33,091 people in the U.S.[1] In addition, deaths by drug overdose, including overdose from prescription opioids, are now the leading cause of injury death in the U.S.
* * *
FDA is taking this action against 247Med because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products that you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
Table of Websites:
Connecting URL
 
eupainrelief.com
painaz.com
webmedlife.com
125pills.com
buyeumeds.com
myeupro.com
247medication.com
Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

[1] Drug Overdose Death Data, Centers for Disease Control and Prevention, athttps://www.cdc.gov/drugoverdose/data/statedeaths.html [Accessed August 28, 2017].

FDA Warning Letter – Global Drug Supply

Leave a comment

TO: Global Drug Supply
FROM: The United States Food and Drug Administration
RE: Shipment of Unapproved New Drugs and Misbranded Drugs to the United
States
DATE: December 6th, 2016
WARNING LETTER
The United States Food and Drug Administration (FDA) has determined that your firm
causes the introduction of unapproved new drugs and misbranded drugs into the United
States (U.S.) by shipping to U.S. consumers in violation of sections 301(a), 301(d), and
505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a),
331(d), and 355(a)]. FDA requests that Global Drug Supply immediately cease shipping
violative drug products to U.S. consumers.
UNAPPROVED NEW DRUGS
Global Drug Supply dispenses and ships unapproved new drugs directly to individual
U.S. consumers on behalf of Canadadrugs.com, an internet pharmacy from which U.S.
consumers purchase violative drug products.1
The drug products shipped by Global Drug
Supply are represented as being equivalent to U.S. approved drug products that are
indicated to treat serious conditions including (but not limited to) seizures, Parkinson’s,
hypertension, depression, and asthma. Because these products are intended for use in the
diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect
the structure or function of the body, these products are drugs within the meaning of
section 201(g) of the FD&C Act [21 U.S.C. § 321(g)]. These products are also new
drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they
are not generally recognized as safe and effective for their labeled uses. New drugs may
not be legally introduced or delivered for introduction into interstate commerce without
prior approval from FDA as described in section 505(a) of the FD&C Act [21 U.S.C. §
355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C.
§ 355] are in effect for these products. Accordingly, their introduction or delivery for
introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C
Act [21 U.S.C. §§ 331(d) and 355(a)].

1
Canadadrugs.com and Global Drug Supply are both under criminal indictment in the U.S. District Court
for the District of Montana for engaging in the illegal importation of unapproved new drugs, misbranded
drugs, and counterfeit drugs for sale and distribution to physicians and physician office practices in the U.S.
(The charges contained in the Indictments are merely accusations and the defendants are presumed
innocent unless and until proven guilty.)
Canadadrugs.com received an FDA Warning Letter in 2012 for causing the introduction of misbranded and
unapproved drugs into the U.S. See
http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm321068.htm.
Page 2
FDA physically examined packages imported to the U.S. by Global Drug Supply that
were determined, based on shipping labels, prescription order forms, and product labeling
to contain unapproved new drugs.
One example of an unapproved new drug shipped by Global Drug Supply to a U.S.
consumer is Pristiq. While Pristiq is the name of an FDA-approved prescription drug, the
product labeling for the drug shipped to the U.S. from Global Drug Supply is intended for
Australia. For example, the product labeling states, “Pfizer Australia Pty Ltd” and refers
to medical information available at “Australia 1800 675 229” and
“medicalaffairs.anzpfizer.com.” In the U.S., Pristiq is approved for the treatment of
depression. Shipping an unapproved version of this drug to U.S. consumers is particularly
concerning given that FDA-approved Pristiq bears a boxed warning, commonly referred
to as a “black box warning,” which is the strongest warning FDA requires, indicating that
the drug carries a significant risk of serious or even life-threatening adverse effects. The
boxed warning addresses suicidal thoughts or actions. There have also been reports of
several serious adverse reactions associated with the use of Pristiq such as a potentially
life-threatening condition called serotonin syndrome that can happen when Pristiq is
taken with certain other medicines. Serotonin syndrome can cause serious changes in
how the brain, muscles, heart and blood vessels, and digestive system work. In addition,
Pristiq can cause other serious side effects such as new or worsened high blood pressure,
abnormal bleeding or bruising, and visual problems.
Another example of an unapproved new drug shipped by Global Drug Supply to a U.S.
consumer is Exforge. While Exforge is the name of an FDA-approved prescription drug
indicated for the treatment of high blood pressure, the product labeling for the drug
shipped to the U.S. from Global Drug Supply states that it is distributed in Australia.
Shipping an unapproved version of Exforge to U.S. consumers is especially concerning
given that FDA-approved Exforge bears a boxed warning regarding harm or death to an
unborn baby. Exforge product shipped to the U.S. by Global Drug Supply contains no
such boxed warning. In addition, the FDA-approved product labeling for Exforge
includes warnings and precautions regarding low blood pressure, risk of heart attack or
worsening chest pain, decreased kidney function, and increased potassium levels in the
blood. There have been reports of several adverse reactions associated with the use of
Exforge including, but not limited to, swelling of the hands, ankles, or feet, nasal
congestion or sore throat, head or chest cold, and dizziness.
MISBRANDED DRUGS:
Because drugs shipped by Global Drug Supply appear to be manufactured and marketed
for countries other than the U.S., they are unapproved new drugs under the FD&C Act, as
described above. A drug is misbranded under section 502(f)(1) of the FD&C Act [21
U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s).
“Adequate directions for use” means directions under which a layperson can use a drug
safely and for the purposes for which it is intended (21 CFR 201.5). The drug products
shipped by Global Drug Supply purport to treat conditions that are not amenable to selfdiagnosis
and treatment by persons who are not medical practitioners. Therefore,
adequate directions for use cannot be written for these drug products, and they must
qualify for one of the exemptions to 502(f)(1) to avoid being misbranded The exemption
Page 3
to 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] found at 21 CFR § 201.100 does
not apply to unapproved new drugs because that exemption requires that such drugs bear
“the labeling authorized by the approved new drug application.” Furthermore,
unapproved new prescription drugs also do not qualify for the exemption set forth at 21
CFR 201.115, which also requires an approved new drug application (NDA) or active
investigational new drug application (IND). Consequently, a prescription drug that is a
new drug and has not been approved by FDA or is not subject to an exemption from the
premarketing approval requirements under the FD&C Act cannot qualify for the
exemptions to 502(f)(1). Because none of the exemptions to 502(f)(1) apply, the labeling
for the drug products shipped by Global Drug Supply fails to bear adequate directions for
the intended uses, and the products are therefore misbranded under section 502(f)(1) of
the FD&C Act [21 U.S.C. § 352(f)(1)]. By shipping these products to U.S. consumers,
Global Drug Supply is causing the introduction of misbranded drugs into interstate
commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
Additional examples of misbranded and unapproved new drugs that have been shipped by
Global Drug Supply to U.S. consumers are noted in the table below.* This list may not be
all-inclusive.
Generic Name Brand Name
Budesonide/formoterol    Vannair
Bupropion Zyban
Celecoxib Celebrex
Conjugated Estrogen Premarin
Estrogens, Conjugated/Medroxyprogesterone Premia
Duloxetine Cymbalta
Escitalopram Lexapro
Estradiol Estradot
Estradiol/Norethindrone Estalis
Ezetimibe Ezetrol
Fexofenadine Telfast
Finasteride Regen
Fluticasone Flixotide
Fluticasone/Salmeterol Seretide
Hydroxychloroquine Plaquenil
Metoprolol CR Betaloc CR
Pentosan Elmiron
Phenytoin Dilantin
Pramipexole Sifrol
Rosuvastatin Crestor
Salbutamol/Ipratropium Duolin
Sildenafil Viagra
Tazarotene Zorac
Telmisartan/Hydrochlrothiazide Micardis Plus
Tretinoin Retrieve
Valsartan/Hydrochlorothiazide Co-Diovan
*Several of the accompanying labels purport that the shipped drug is equivalent to an FDA-approved drug.
Page 4
CONCLUSION:
FDA is taking this action against Global Drug Supply because of the risks posed by its
conduct in causing the importation of drugs that are unapproved and misbranded into the
U.S. FDA’s regulation and oversight of the drug approval process protects consumers by
requiring rigorous scientific standards for new drug approval, labeling review for
accuracy and completeness, and manufacturing procedures and testing performed under
closely controlled conditions at FDA-registered and inspected facilities.
Unapproved foreign versions of FDA-approved drugs often have different trade names or
manufacturers and may have substantially different risk profiles due to changes in drug
formulations, drug delivery methods, directions for use, or contraindications and
warnings. Any and all of these factors may harm consumers who are unaware that they
are not receiving the same medications prescribed by their healthcare practitioners.
Taking an unapproved drug in place of the FDA-approved product can negatively affect
patient outcomes because the health care practitioner may unknowingly make subsequent
treatment decisions based on the patient’s response to the unapproved drug, rather than to
the approved drug that was prescribed. This can also cause potentially dangerous drug
interactions with the patient’s other medications.
This letter is not intended to identify all the ways in which your activities might be in
violation of law. You should promptly cease shipping misbranded and unapproved new
drug products to U.S. consumers and correct any other violations of the FD&C Act.
Failure to do so immediately may result in further regulatory action, including seizure or
injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any
steps you have taken or will take to correct the violations set forth above and to prevent
their recurrence. If the corrective action(s) cannot be completed within 10 working days,
state the reason for the delay and the time within which the correction(s) will be
completed. Your response, and any other inquiries concerning this letter, should be sent
to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForceCDER@fda.hhs.gov.

Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

FDA Warning Letter – CanAmerica Global

Leave a comment
10903 New Hampshire Avenue
Silver Spring, MD 20993

 

TO:        CanAmerica Global
FROM: The United States Food and Drug Administration
RE:        Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet
DATE:   September 19, 2017
WARNING LETTER
The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in U.S. commerce in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
Unapproved New Drugs
 
As labeled, certain products offered for sale through your websites are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or because they are intended to affect the structure or function of the body. These products, as marketed through your websites, are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)], because they are not generally recognized as safe and effective for their labeled uses. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].
An example of an unapproved drug on your websites is injectable epinephrine marketed as “Allerject.” While there is an FDA-approved version of injectable epinephrine on the market in the U.S. offered as “EpiPen,” the product offered for sale on your websites is not the FDA-approved product. There is currently no approved application pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] in effect for “Allerject,” the epinephrine product offered for sale on your websites. Moreover, particularly concerning is that all Allerject devices in Canada were the subject of a nationwide recall in 2015 due to a drug delivery concern associated with a device malfunction. FDA-approved “EpiPen” is a prescription drug used to treat allergic emergencies (anaphylaxis) due to stinging or biting insects, foods, drugs, exercise, or unknown causes.  Offering this unapproved new drug on your websites is particularly concerning given that even FDA-approved epinephrine products are associated with significant risks including warnings regarding serious infections at the injection site and use in patients with heart disease.
 
 
Misbranded Drugs
A drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if it fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
 “Allerject” is an unapproved new drug under the FD&C Act as described above. Because the aforementioned drug is a prescription product intended for condition(s) that are not amenable to self-diagnosis and treatment by a layperson, adequate directions cannot be written such that a layperson can use the product safely for its intended use(s). Consequently, the labeling for this product fails to bear adequate directions for its intended use(s), causing it to be misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]. Because “Allerject” lacks the required FDA approved application, it is not exempt under 21 CFR 201.115 from the requirements of section 502(f)(1) of the FD&C Act. By offering this drug for sale to U.S. consumers, your websites are causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].
***
FDA is taking this action against CanAmerica Global because of the inherent risk to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not have the same assurance of safety and effectiveness as those drugs subject to FDA oversight, and drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.
This letter is not intended to identify all the ways in which your activities might be in violation of law. It is your responsibility to ensure that all products you market are in compliance with the FD&C Act and its implementing regulations.  You should take prompt action to correct the violations noted above as well as any other violations of the FD&C Act (which would include the offer for sale of all unapproved and/or misbranded drug products by your websites, not just the products noted above).  Failure to correct violations may result in FDA regulatory action, including seizure or injunction, without further notice.
Please notify this office in writing within 10 working days of receipt of this letter of any steps you have taken or will take to correct the violations set forth above and to prevent their recurrence.
If the corrective action(s) cannot be completed within 10 working days, state the reason for the delay and the time within which the correction(s) will be completed. Your response and any other inquiries concerning this letter should be sent to FDA’s Internet Pharmacy Task Force at FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov.
 
Table of Websites:
 
Connecting URL
locuspharma.com
greyspharmacy.com
77canada.com
genericdrugoutlet.com
pharmadd.com
pricechoprx.com
travantipharma.com
77canadapharmacy.com
77canadapharmacy.net
bestindiapharmacy.com
buckadaypharmacy.com
bulkdrugsonline.com
canadapharmacyselect.com
canadian-pharmacies-online.net
canamerica.com
canamericadrugs.com
canamericaglobal.com
canamericaglobal.net
discountvaluemeds.com
freeshippingmedication.com
genericdrugsuperstore.com
libertydiscountdrugstore.com
medcentercanada.net
medsearchonline.com
panthermeds.net
pioneerfund.org
realfastdrugstore.net
rfdrugstore.net
worldwidedrugplan.com
americanameds.com
medcentercanada.com
rfdrugstore.com
thedrugcompany.com
Sincerely,
/s/
Thomas Christl
Director
Office of Drug Security, Integrity, and Response
Office of Compliance
Center for Drug Evaluation and Research
Food and Drug Administration

WhoIs canadianbestpills.com

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

 

canadabeststore.png

Address lookup
canonical name:canadianbestpills.com
aliases
addresses:81.177.141.101
Domain Whois record

Queried whois.internic.net with “dom canadianbestpills.com

Domain Name: CANADIANBESTPILLS.COM
Registry Domain ID: 1965211713_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.onlinenic.com
Registrar URL: http://www.onlinenic.com
Updated Date: 2017-08-01T22:37:05Z
Creation Date: 2015-10-01T15:48:15Z

Registry Expiry Date: 2018-10-01T15:48:15Z
Registrar: OnlineNIC, Inc.
Registrar IANA ID: 82

Registrar Abuse Contact Email: abuse@onlinenic.com
Registrar Abuse Contact Phone: +1.510-769-8492

Domain Status: clientTransfer

Name Server: NS1.JINO.RU
Name Server: NS2.JINO.RU
Name Server: NS3.JINO.RU
Name Server: NS4.JINO.RU
DNSSEC: unsigned
URL of the ICANN Whois

Last update of whois database: 2017-09-27T14:11:19Z
Queried whois.onlinenic.com with “canadianbestpills.com

Domain Name: canadianbestpills.com
Registry Domain ID: 5530000_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.onlinenic.com
Registrar URL: http://www.onlinenic.com

Updated Date: 2017-08-01T18:36:58Z
Creation Date: 2015-10-01T04:00:00Z

Registrar Registration Expiration Date: 2018-10-01T04:00:00Z
Registrar: Onlinenic Inc
Registrar IANA ID: 82
Registrar Abuse Contact Email: onlinenic-enduser@onlinenic.com
Registrar Abuse Contact Phone: +1.510-769-8492
Domain Status: clientTransferProhibited

Registry Registrant ID: Not Available From Registry
Registrant Name: Domain ID Shield Service
Registrant Organization: Domain ID Shield Service CO., Limited

Registrant Street: 5/F Hong Kong Trade Centre, 161-167 DesVoeux Road Central, Hong Kong
Registrant City: Hong Kong
Registrant State/Province: Hong Kong
Registrant Postal Code: 999077
Registrant Country: CN
Registrant Phone: +852.21581835
Registrant Fax: +852.30197491
Registrant Email: 5530000729104@domainidshield.com

Registry Admin ID: Not Available From Registry
Admin Name: Domain ID Shield Service
Admin Organization: Domain ID Shield Service CO., Limited
Admin Street: 5/F Hong Kong Trade Centre, 161-167 DesVoeux Road Central, Hong Kong
Admin City: Hong Kong
Admin State/Province: Hong Kong
Admin Postal Code: 999077
Admin Country: CN
Admin Phone: +852.21581835
Admin Phone Ext:
Admin Fax: +852.30197491

Admin Email: 5530000729101@domainidshield.com
Registry Tech ID: Not Available From Registry
Tech Name: Domain ID Shield Service
Tech Organization: Domain ID Shield Service CO., Limited
Tech Street: 5/F Hong Kong Trade Centre, 161-167 DesVoeux Road Central, Hong Kong
Tech City: Hong Kong
Tech State/Province: Hong Kong
Tech Postal Code: 999077
Tech Country: CN
Tech Phone: +852.21581835
Tech Fax: +852.30197491
Tech Email: 5530000729102@domainidshield.com

Name Server: ns1.jino.ru
Name Server: ns2.jino.ru
Name Server: ns3.jino.ru
Name Server: ns4.jino.ru

DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-08-01T18:36:58Z <<<

WHOIS 24×7-DRUGSSHOP.COM

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

265webstoreRX.png
The following A records are set to 46.29.218.6:

  1. 1st-canadian-healthcare.com,
  2. 247drugsshop.com,
  3. 247worldstorerxe.com,
  4. 247worldstorewrx.com,
  5. 247worldstorewrxe.com,
  6. 24h-drugsshop.com,
  7. 24×7-drugsshop.com,
  8. 365worldstorerxe.com,
  9. 365worldstorewrx.com,
  10. 365worldstorewrxe.com,
  11. all-canada-drugs.com,
  12. best-healthstore.com,
  13. canadameds-24.com,
  14. canadian-drugsstore-24×7.com,
  15. canadian-meds-24.com,
  16. canadian-pharmshop-24×7.com,
  17. canadian-pills-store.com,
  18. canadian-store-24h.com,
  19. canadianmeds-24.com,
  20. de-online-apotheke.com,
  21. eu-medshop.com,
  22. eu-medstore.com,
  23. eu-pharmacy24.com,
  24. euro-pharm-store.com,
  25. euro-pharm.net,
  26. euro-pharm247.com,
  27. farmacia-online-italia.com,
  28. fast-pills-247.com,
  29. fast-pills.com, genericiop.net,
  30. good-drugs.com,
  31. healthcare-24h.com,
  32. healthcarepillsrx.com,
  33. healthytablets.com,
  34. med-mall24.com,
  35. med-shop365.com,
  36. meds-247.com,
  37. meds-365.com,
  38. my-reorder.com,
  39. mycanadianrxmeds.com,
  40. mytabsonline.com,
  41. ns1.ns-for-seo.com,
  42. ns1.seoparking.info,
  43. online-drugsstore.com,
  44. online-secure-shop.com,
  45. onlinepharmacy-24h.com,
  46. pharmshop365.com,
  47. pillsmart.net,
  48. pillsup.com,
  49. rxcanadianmarket.com,
  50. rxcanadianshop.com,
  51. rxlegal.com,
  52. rxmedcanadas.com,
  53. rxmeds24.net,
  54. rxpharmacy24.org,
  55. sale-drugs.com,
  56. top-canadian-healthcare.com,
  57. top-canadian-pharmacy.com,
  58. top-canadian-shop.com,
  59. top-online-pillsstore.com,
  60. topcanadadrugs.net,
  61. topcanadianshop.com,
  62. topdrugshop24-7.com,
  63. topdrugsshop.com,
  64. trustpharmaproducts.com,
  65. trustpharmshop.com,
  66. vipmdline.com,
  67. walmart-rx-store.com
  68. worldbankmed.com

WhoIs CanadianBreeze.net/canadian-breeze.net

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

canadian-breeze.png

+760-284-3222/7602843222
+4420-3286-3286

canadian-breeze.net :198.37.112.178 resolves to 112.37.198-178.dc74.net.
The following A records are set to 198.37.112.178:

  1. 24online-med.org
  2. canadian-breeze.net
  3. canadian-pharmacy-ltd.com
  4. cheaphealthyman.com
  5. mdonlinestore.co
  6. ns2.amandaqdm.biz

____________________________

RAW WHOIS DATA
Domain name: canadianbreeze.net
Registrar Domain ID:
Registrar WHOIS Server: whois.todaynic.com

Registrar URL: http://www.now.cn/
Update Date: 2014-03-08
Creation Date: 2014-03-08 16:50:17
Registrar Registration Expiration Date: 2016-03-07
Registrar: 2014-03-08 16:50:17
Registrar IANA ID: 697
Registrar Abuse Contact Email: email@now.cn
Registrar Abuse Contact Phone: +86. 07563810552
Domain Status: clientTransferProhibited

Registry Registrant ID:
Registrant Name: Jackie R. Algarin
Registrant Organization: Jackie R. Algarin
Registrant Address: 1657 Mahlon Street
Registrant City: New Brunswick
Registrant Province/state: XZ
Registrant Country: US
Registrant Postal Code: 08901
Registrant Phone: +1.732-937-7314
Registrant Fax: +1.7329377314
Registrant Email: email@gmail.com
Registry Admin ID: 43576415

Admin Name: Jackie R. Algarin
Admin Organization: Jackie R. Algarin
Admin Address: 1657 Mahlon Street
Admin City: New Brunswick
Admin Province/state: XZ
Admin Country: US
Admin Postal Code: 08901
Admin Phone: +1.732-937-7314
Admin Fax: +1.7329377314

Admin Email: email@gmail.com
Admin Email EXT:
Registry Tech ID: 43576416
Tech Name: Jackie R. Algarin
Tech Organization: Jackie R. Algarin
Tech Address: 1657 Mahlon Street
Tech City: New Brunswick
Tech Province/state: XZ
Tech Country: US
Tech Postal Code: 08901
Tech Phone: +1.7329377314
Tech Fax: +1.7329377314
Tech Email: email@gmail.com

Billing Contact:
Billing Name: Jackie R. Algarin
Billing Organization: Jackie R. Algarin
Billing Address: 1657 Mahlon Street
Billing City: New Brunswick
Billing Province/state: XZ
Billing Country: US
Billing Postal Code: 08901
Billing Phone: +1.7329377314
Billing Fax: +1.732-937-7314
Billing Email: email@gmail.com

Name Server: ns1.seoparking.biz
Name Server: ns2.seoparking.biz

Who is ePharmacies.com?

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

 

ePharmacies.com is committed to helping customers find safe, high-quality, and affordable medications through reputable online pharmacies. We seek to raise awareness about rising medication costs, empowering consumers so they can increase their health and well-being.

epharamies

  1. vimaxpills.shop
  2. planetdrugsdirect.com
  3. CheapRXmeds.com
  4. canadadrugs.com
  5. canadadrugcenter.com
  6. discountdrugsfromcanada.com
  7. ivfprescriptions.com
  8. medicationdiscountcard.com
  9. drugswww.com
  10. doctorsolve.com
  11. planetdrugsdirect.com
  12. goodrx.com
  13. topmedonlinestore.com
  14. http://www.asomf.org
  15. epharmacies.com
  16. edrugsearch.com
  17. drugs-med.com
  18. herbalsupplementshealth.com
  19. Prescriptiongiant.com
  20. topiramate365.com
  21. bestvito.eu

Address lookup
canonical name:epharmacies.com
aliases
addresses:2400:cb00:2048:1::681b:bc2c
2400:cb00:2048:1::681b:bd2c
104.27.188.44
104.27.189.44
Domain Whois record

Queried whois.internic.net with “dom epharmacies.com”…

Domain Name: EPHARMACIES.COM
Registry Domain ID: 63385079_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.domain.com
Registrar URL: http://www.domain.com

Updated Date: 2016-01-29T14:35:05Z
Creation Date: 2001-02-22T11:44:37Z
Registry Expiry Date: 2019-02-22T11:44:35Z

Registrar: Domain.com, LLC
Registrar IANA ID: 886
Registrar Abuse Contact Email: compliance@domain-inc.net
Registrar Abuse Contact Phone: 602-226-2389

Domain Status: clientTransferProhibited
Domain Status: clientUpdateProhibited

Name Server: MARY.NS.CLOUDFLARE.COM
Name Server: PHIL.NS.CLOUDFLARE.COM
DNSSEC: unsigned

URL of the ICANN Whois Inaccuracy Complaint

>>> Last update of whois database: 2017-09-22T14:06:22Z <<<
Queried whois.domain.com with "epharmacies.com"…

Domain Name: EPHARMACIES.COM
Domain ID: 63385079_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.domain.com
Registrar URL: http://www.domain.com
Updated Date: 2016-01-29T14:35:05Z
Creation Date: 2001-02-22T11:44:37Z
Registrar Registration Expiration Date: 2019-02-22T11:44:35Z

Registrar: Domain.com, LLC
Registrar IANA ID: 886
Registrar Abuse Contact
Registrar Abuse Contact Phone: +1.6027165396
Reseller: MyDomain

Domain Status: clientTransferProhibited
Domain Status: clientUpdateProhibited

Registry Registrant ID:
Registrant Name: Domain Privacy Service FBO Registrant.
Registrant Organization: Domain Privacy Service FBO Registrant.

Registrant Street: 10 Corporate Drive Suite 300
Registrant City: Burlington
Registrant State/Province: MA
Registrant Postal Code: 01803
Registrant Country: US
Registrant Phone: +1.6027165339
Registrant Email: epharmacies.com@domainprivacygroup.com

Registry Admin ID:
Admin Name: Domain Privacy Service FBO Registrant.
Admin Organization: Domain Privacy Service FBO Registrant.
Admin Street: 10 Corporate Drive Suite 300
Admin City: Burlington
Admin State/Province: MA
Admin Postal Code: 01803
Admin Country: US
Admin Phone: +1.6027165339
Admin Email: epharmacies.com@domainprivacygroup.com

Registry Tech ID:
Tech Name: Domain Privacy Service FBO Registrant.
Tech Organization: Domain Privacy Service FBO Registrant.
Tech Street: 10 Corporate Drive Suite 300
Tech City: Burlington
Tech State/Province: MA
Tech Postal Code: 01803
Tech Country: US
Tech Phone: +1.6027165339
Tech Email: epharmacies.com@domainprivacygroup.com

Network Whois record
Queried whois.arin.net with “n 104.27.188.44″…

NetRange: 104.16.0.0 – 104.31.255.255
CIDR: 104.16.0.0/12
NetName: CLOUDFLARENET
NetHandle: NET-104-16-0-0-1
Parent: NET104 (NET-104-0-0-0-0)
NetType: Direct Assignment
OriginAS: AS13335
Organization: Cloudflare, Inc. (CLOUD14)
RegDate: 2014-03-28
Updated: 2017-02-17
Comment: All Cloudflare abuse reporting can be done via https://www.cloudflare.com/abuse
Ref: https://whois.arin.net/rest/net/NET-104-16-0-0-1

OrgName: Cloudflare, Inc.
OrgId: CLOUD14
Address: 101 Townsend Street
City: San Francisco
StateProv: CA
PostalCode: 94107
Country: US
RegDate: 2010-07-09
Updated: 2017-02-17
Comment: All Cloudflare abuse reporting can be done via https://www.cloudflare.com/abuse
Ref: https://whois.arin.net/rest/org/CLOUD14

OrgNOCHandle: NOC11962-ARIN
OrgNOCName: NOC
OrgNOCPhone: +1-650-319-8930
OrgNOCEmail: noc@cloudflare.com
OrgNOCRef: https://whois.arin.net/rest/poc/NOC11962-ARIN

OrgTechHandle: ADMIN2521-ARIN
OrgTechName: Admin
OrgTechPhone: +1-650-319-8930
OrgTechEmail: admin@cloudflare.com
OrgTechRef: https://whois.arin.net/rest/poc/ADMIN2521-ARIN

OrgAbuseHandle: ABUSE2916-ARIN
OrgAbuseName: Abuse
OrgAbusePhone: +1-650-319-8930
OrgAbuseEmail: abuse@cloudflare.com
OrgAbuseRef: https://whois.arin.net/rest/poc/ABUSE2916-ARIN

RNOCHandle: NOC11962-ARIN
RNOCName: NOC
RNOCPhone: +1-650-319-8930
RNOCEmail: noc@cloudflare.com
RNOCRef: https://whois.arin.net/rest/poc/NOC11962-ARIN

RAbuseHandle: ABUSE2916-ARIN
RAbuseName: Abuse
RAbusePhone: +1-650-319-8930
RAbuseEmail: abuse@cloudflare.com
RAbuseRef: https://whois.arin.net/rest/poc/ABUSE2916-ARIN

RTechHandle: ADMIN2521-ARIN
RTechName: Admin
RTechPhone: +1-650-319-8930
RTechEmail: admin@cloudflare.com
RTechRef: https://whois.arin.net/rest/poc/ADMIN2521-ARIN

WhoIs TopMedOnlineStore.com

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

Topmedstore

http://www.TopMedOnlineStore.com Information

Site Title
Online Pharmacy No Prescription ! Top Medical Online Store ! Buy Cheap Generic Medication
Meta Description
This Top Online Drugstore for generic pills, that provides best quality, lowest prices and worldwide shipping. We have guaranted 100% sequrity. Here you can buy Viagra online, generic Cialis, cheap Levitra.
TopMedOnlineStore.com Support Service
+1 855-306-9027,
+1 316-202-5166,
+1 773-270-2818
_____________________

  1. vimaxpills.shop
  2. planetdrugsdirect.com
  3. CheapRXmeds.com
  4. canadadrugs.com
  5. canadadrugcenter.com
  6. discountdrugsfromcanada.com
  7. ivfprescriptions.com
  8. medicationdiscountcard.com
  9. drugswww.com
  10. doctorsolve.com
  11. planetdrugsdirect.com
  12. goodrx.com
  13. topmedonlinestore.com
  14. http://www.asomf.org
  15. epharmacies.com
  16. edrugsearch.com
  17. drugs-med.com
  18. herbalsupplementshealth.com
  19. Prescriptiongiant.com
  20. topiramate365.com
  21. bestvito.eu

Address lookup

canonical name:topmedonlinestore.com
aliases
addresses:37.1.215.147
Domain Whois record

Queried whois.internic.net with “dom TopMedOnlineStore.com

Domain Name: TOPMEDONLINESTORE.COM
Registry Domain ID: 1746434451_DOMAIN_COM-VRSN

Registrar WHOIS Server: whois.registrar.eu
Registrar URL: http://www.openprovider.com

Updated Date: 2017-08-18T16:39:21Z
Creation Date: 2012-09-20T20:01:38Z

Registry Expiry Date: 2018-09-20T20:01:38Z
Registrar: Hosting Concepts B.V. d/b/a Openprovider
Registrar IANA ID: 1647
Registrar Abuse Contact Email: abuse@registrar.eu
Registrar Abuse Contact Phone: +31.104482297

Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited

Name Server: NS1.TOPMEDONLINESTORE.COM
Name Server: NS2.TOPMEDONLINESTORE.COM
DNSSEC: unsigned

Last update of whois database: 2017-09-22T13:29:11Z

Queried whois.registrar.eu with “TopMedOnlineStore.com”…

Domain Name: topmedonlinestore.com
Registry Domain ID: 1746434451_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.registrar.eu
Registrar URL: http://www.registrar.eu
Updated Date: 2017-08-18T18:39:22Z
Creation Date: 2012-09-20T22:01:38Z

Registrar Registration Expiration Date: 2018-09-20T20:01:38Z
Registrar: Hosting Concepts B.V. d/b/a Openprovider
Registrar IANA ID: 1647
Registrar Abuse Contact Email: abuse@registrar.eu
Registrar Abuse Contact Phone: +31.104482297
Domain Status: ok https://icann.org/epp#ok

Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited

Registry Registrant ID: AS907591-RU
Registrant Name: Andrei Sokolovsky
Registrant Organization: Andrei Sokolovsky
Registrant Street: Kalinina ul., 139
Registrant City: Semikarakorsk
Registrant State/Province: Rostovskaya
Registrant Postal Code: 346630
Registrant Country: RU
Registrant Phone: +7.8632001427
Registrant Fax: +7.8632001427
Registrant Email: talmor@free-id.ru

Registry Admin ID: AS907591-RU
Admin Name: Andrei Sokolovsky
Admin Organization: Andrei Sokolovsky
Admin Street: Kalinina ul., 139
Admin City: Semikarakorsk
Admin State/Province: Rostovskaya
Admin Postal Code: 346630
Admin Country: RU
Admin Phone: +7.8632001427
Admin Fax: +7.8632001427
Admin Email: talmor@free-id.ru

Registry Tech ID: AS907591-RU
Tech Name: Andrei Sokolovsky
Tech Organization: Andrei Sokolovsky
Tech Street: Kalinina ul., 139
Tech City: Semikarakorsk
Tech State/Province: Rostovskaya
Tech Postal Code: 346630
Tech Country: RU
Tech Phone: +7.8632001427
Tech Fax: +7.8632001427
Tech Email: talmor@free-id.ru

Name Server: ns1.topmedonlinestore.com
Name Server: ns2.topmedonlinestore.com

DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-09-22T13:29:20Z <<<
Network Whois record

Queried whois.ripe.net with "-B 37.1.215.147"…

% Information related to '37.1.208.0 – 37.1.215.255'

% Abuse contact for '37.1.208.0 – 37.1.215.255' is 'abuse@3nt.com'

inetnum: 37.1.208.0 – 37.1.215.255
netname: INFERNO-NL-DE
descr: ********************************************************
descr: * We provide virtual and dedicated servers on this Subnet.
descr: *
descr: * Those services are self managed by our customers
descr: * therefore, we are not using this IP space ourselves
descr: * and it could be assigned to various end customers.
descr: *
descr: * In case of issues related with SPAM, Fraud,
descr: * Phishing, DDoS, portscans or others,
descr: * feel free to contact us with relevant info
descr: * and we will shut down this server: abuse@3nt.com
descr: ********************************************************
country: US
admin-c: TNTS-RIPE
tech-c: TNTS-RIPE
status: ASSIGNED PA
mnt-by: MNT-3NT
mnt-routes: swiftway-mnt
remarks: 3NT Hosting Network
remarks: Technical issues…………..: support@3nt.com
remarks: Services request…………..: sales@3nt.com
remarks: Abuse departament………….: abuse@3nt.com
remarks: Corporate web site…………: http://www.3nt.com
created: 2011-12-13T12:46:29Z
last-modified: 2012-09-21T10:14:02Z
source: RIPE

person: Daniel O'Donoghue
address: 3NT SOLUTIONS LLP
address: 10 GREAT RUSSELL STREET, SUITE 4084
address: WC1B 3BQ, LONDON, UK
phone: +442081333030
e-mail: info@3nt.com
abuse-mailbox: abuse@3nt.com
nic-hdl: TNTS-RIPE
mnt-by: MNT-3NT
created: 2011-10-20T12:31:42Z
last-modified: 2016-10-25T20:22:11Z
source: RIPE

% Information related to '37.1.208.0/21AS35017'

route: 37.1.208.0/21
descr: DARL-TELECOM
origin: AS35017
mnt-by: AS35017-MNT
notify: ripe@swiftnoc.com
created: 2011-12-30T22:32:21Z
last-modified: 2011-12-30T22:32:21Z
source: RIPE

% This query was served by the RIPE Database Query Service version 1.89.2 (ANGUS)
DNS records

DNS query for topmedonlinestore.com returned an error from the server: Refused

DNS query for 147.215.1.37.in-addr.arpa returned an error from the server: NameError

name class type data time to live
topmedonlinestore.com IN A 37.1.215.147 14398s (03:59:58)
topmedonlinestore.com IN NS ns2.domain.com 14400s (04:00:00)
topmedonlinestore.com IN NS ns1.domain.com 14400s (04:00:00)
— end —
URL for this output | return to CentralOps.net, a service of Hexillion

WhoIs lloyds-pharma.com

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

  1. viagracialisfreetrial.com
  2. viagraoffers.com
  3. viagrapricefast.com
  4. viagrawithoutadoctorprescriptionfor.com
  5. viagrawithoutadoctorprescriptionprice.com
  6. viagrawithoutseeingadoctor.com

lloyds-pharma-1505610254466.png

Address lookup
canonical name :lloyds-pharma.com
aliases
addresses 149.56.190.105
Domain Whois record

Queried whois.internic.net with “dom lloyds-pharma.com”…

Domain Name: LLOYDS-PHARMA.COM
Registry Domain ID: 2027140780_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.namesilo.com
Registrar URL: http://www.namesilo.com
Updated Date: 2017-08-18T12:50:25Z
Creation Date: 2016-05-10T10:55:21Z
Registry Expiry Date: 2018-05-10T10:55:21Z
Registrar: NameSilo, LLC
Registrar IANA ID: 1479
Registrar Abuse Contact Email: abuse@namesilo.com
Registrar Abuse Contact Phone: +1.4805240066
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.EDGESERV.COM
Name Server: NS2.EDGESERV.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-17T00:57:47Z <<<
Queried whois.namesilo.com with "lloyds-pharma.com"…

Domain Name: lloyds-pharma.com
Registry Domain ID: 2027140780_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.namesilo.com
Registrar URL: https://www.namesilo.com/

Updated Date: 2017-09-11
Creation Date: 2016-05-10

Registrar Registration Expiration Date: 2018-05-10
Registrar: NameSilo, LLC
Registrar IANA ID: 1479

Registrar Abuse Contact Email: abuse@namesilo.com
Registrar Abuse Contact Phone: +1.4805240066

Status: clientTransferProhibited

Registry Registrant ID:
Registrant Name: Domain Administrator
Registrant Organization: See PrivacyGuardian.org
Registrant Street: 1928 E. Highland Ave. Ste F104 PMB# 255
Registrant City: Phoenix
Registrant State/Province: AZ
Registrant Postal Code: 85016
Registrant Country: US
Registrant Phone: +1.3478717726
Registrant Email: pw-6626528a20bcefb8e8f4c130f61e5d50@privacyguardian.org

Registry Admin ID:
Admin Name: Domain Administrator
Admin Organization: See PrivacyGuardian.org
Admin Street: 1928 E. Highland Ave. Ste F104 PMB# 255
Admin City: Phoenix
Admin State/Province: AZ
Admin Postal Code: 85016
Admin Country: US
Admin Phone: +1.3478717726
Admin Email: pw-6626528a20bcefb8e8f4c130f61e5d50@privacyguardian.org

Registry Tech ID:
Tech Name: Domain Administrator
Tech Organization: See PrivacyGuardian.org
Tech Street: 1928 E. Highland Ave. Ste F104 PMB# 255
Tech City: Phoenix
Tech State/Province: AZ
Tech Postal Code: 85016
Tech Country: US
Tech Phone: +1.3478717726
Tech Email: pw-6626528a20bcefb8e8f4c130f61e5d50@privacyguardian.org

Name Server: ns1.edgeserv.com
Name Server: ns2.edgeserv.com
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
Last update of WHOIS database: 2017-09-16 17:58:05

WhoIs ushealthstore365.com

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

Toll Free (US): telephone 800-532-4808
Regular US: telephone:718-475-9088
UK: telephone: +44 203011 0241

ushealthstore365-1505605978578.png

Address lookup

canonical name ushealthstore365.com.
aliases
addresses 5.189.165.33
Domain Whois record

Queried whois.internic.net with “dom ushealthstore365.com”…

Domain Name: USHEALTHSTORE365.COM
Registry Domain ID: 2127993354_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ascio.com
Registrar URL: http://www.ascio.com
Updated Date: 2017-08-02T15:07:50Z
Creation Date: 2017-05-25T20:59:51Z
Registry Expiry Date: 2018-05-25T20:59:51Z
Registrar: Ascio Technologies, Inc. Danmark – Filial af Ascio technologies, Inc. USA
Registrar IANA ID: 106
Registrar Abuse Contact Email: abuse@ascio.com
Registrar Abuse Contact Phone: +442070159370
Domain Status: ok https://icann.org/epp#ok
Name Server: NS1.DEBASEDHOSTING.COM
Name Server: NS2.DEBASEDHOSTING.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-16T23:44:29Z <<>> Last update of WHOIS database: 2017-09-16T23:44:35Z <<<
Network Whois record

Queried whois.ripe.net with "-B 5.189.165.33"…

% Information related to '5.189.160.0 – 5.189.175.255'

% Abuse contact for '5.189.160.0 – 5.189.175.255' is 'abuse@contabo.de'

inetnum: 5.189.160.0 – 5.189.175.255
netname: CONTABO
descr: Contabo GmbH
country: DE
org: ORG-GG22-RIPE
admin-c: MH7476-RIPE
tech-c: MH7476-RIPE
status: ASSIGNED PA
mnt-by: MNT-CONTABO
mnt-lower: MNT-CONTABO
mnt-domains: MNT-CONTABO
mnt-routes: MNT-CONTABO
created: 2014-04-27T12:56:22Z
last-modified: 2014-04-27T12:56:22Z
source: RIPE

organisation: ORG-GG22-RIPE
org-name: Contabo GmbH
org-type: LIR
remarks: * Please direct all complaints about Internet abuse like Spam, hacking or scans *
remarks: * to abuse@contabo.de . This will guarantee fastest processing possible. *
address: Aschauer Strasse 32a
address: 81549
address: Munchen
address: GERMANY
phone: +498921268372
fax-no: +498921665862
e-mail: michael.herpich@contabo.de
abuse-c: MH12453-RIPE
mnt-ref: RIPE-NCC-HM-MNT
mnt-ref: MNT-CONTABO
abuse-mailbox: abuse@contabo.de
mnt-by: RIPE-NCC-HM-MNT
mnt-by: MNT-CONTABO
created: 2009-12-09T13:41:08Z
last-modified: 2016-06-14T12:41:42Z
source: RIPE

person: Michael Herpich
address: Contabo GmbH
address: Aschauer Str. 32a
address: 81549 Muenchen
phone: +49 89 21268372
fax-no: +49 89 21665862
nic-hdl: MH7476-RIPE
mnt-by: MNT-CONTABO
created: 2010-01-04T10:41:37Z
last-modified: 2012-12-26T06:13:37Z
source: RIPE

% Information related to '5.189.160.0/20AS51167'

route: 5.189.160.0/20
descr: CONTABO
origin: AS51167
mnt-by: MNT-CONTABO
created: 2014-04-27T12:57:43Z
last-modified: 2014-04-27T12:57:43Z
source: RIPE

% This query was served by the RIPE Database Query Service version 1.89.2 (WAGYU)

WhoIs erection-drugs.net

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

 erectionviagra.png

Toll Free (US): telephone 800-532-4808
Regular US: telephone:718-475-9088
UK: telephone:+44 203011 0241

Sites on IP 188.120.235.244
Displaying items 1 to 25, out of a total of 25

  1. avanafil-online.net/
  2. buy-qnexa.avanafil-online.net/
  3. buyimpotencedrugs.net/
  4. erectilepills.org/
  5. erection-drugs.net/
  6. erectiondrugsonline.com/
  7. impotence-drugs.net/
  8. order-phentermine.com/
  9. sildenafilsideeffects.com/
  10. whatissildenafil.com/
  11. woodeneyewear.net/
  12. woodenglasses.org/
  13. woodenspectacles.net/
  14. avanafil-online.net/
  15. buyimpotencedrugs.net/
  16. erectilepills.org/
  17. erection-drugs.net/
  18. erectiondrugsonline.com
  19. impotence-drugs.net/
  20. http://www.order-phentermine.com/
  21. sildenafilsideeffects.com/
  22. whatissildenafil.com/
  23. woodeneyewear.net/
  24. woodenspectacles.net/
  25. xenical.avanafil-online.net/

inetnum: 188.120.232.0 – 188.120.239.255
netname: THEFIRST-NET
descr: TheFirst-RU clients (WebDC Msk)
country: RU
admin-c: FRST3-RIPE
tech-c: FRST3-RIPE
status: ASSIGNED PA
mnt-by: THEFIRST-MNT
mnt-irt: IRT-THEFIRST
created: 2009-10-30T07:58:49Z
last-modified: 2016-04-20T04:54:07Z
source: RIPE

role: The First JSC Network Operations
address: The First JSC
address: Office 2, 34a, Raduzhny m-r
address: 664017
address: Irkutsk
address: Russian Federation
phone: +7 (495) 663 73 72
fax-no: +7 (3952) 52 57 89
remarks: trouble: ——————————————————-
remarks: trouble: Points of contact for The First CJSC Network Operations
remarks: trouble: ——————————————————-
remarks: trouble: Routing and peering issues: noc@firstvds.ru
remarks: trouble: SPAM issues: abuse@abusehost.ru
remarks: trouble: Mail issues: abuse@abusehost.ru
remarks: trouble: General information: noc@firstvds.ru
remarks: trouble: ——————————————————-
admin-c: AA26905-RIPE
tech-c: ST6386-RIPE
nic-hdl: FRST3-RIPE
mnt-by: THEFIRST-MNT
created: 2014-09-12T07:34:10Z
last-modified: 2016-12-08T09:16:51Z
source: RIPE # Filtered
abuse-mailbox: abuse@abusehost.ru

route: 188.120.224.0/20
descr: TheFirst-RU
origin: AS29182
mnt-by: THEFIRST-MNT
created: 2009-09-14T06:23:39Z
last-modified: 2014-06-10T02:23:40Z
source: RIPE

WhoIs mycanadianpharmacyrx.com

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

mycanadianpharamcyrx.png
Address lookup
canonical name:www.mycanadianpharmacyrx.com
aliases
addresses :195.154.43.60
163.172.111.210
Domain Whois record

Queried whois.internic.net with “dom mycanadianpharmacyrx.com

Domain Name: MYCANADIANPHARMACYRX.COM
Registry Domain ID: 1957204349_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.webnames.ru
Registrar URL: http://www.webnames.ru

Updated Date: 2016-10-04T05:21:57Z
Creation Date: 2015-09-03T13:33:52Z

Registry Expiry Date: 2018-09-03T13:33:52Z
Registrar: Regtime Ltd.
Registrar IANA ID: 1362
Registrar Abuse Contact
Registrar Abuse Contact Phone:
Domain Status: ok

Name Server: NS1.MYCANADIANPHARMACYRX.COM
Name Server: NS2.MYCANADIANPHARMACYRX.COM

DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint

Last update of whois database: 2017-08-14T16:15:36Z

Queried whois.webnames.ru with “mycanadianpharmacyrx.com”…

Domain Name: MYCANADIANPHARMACYRX.COM
Registry Domain ID: 1957204349_DOMAIN_COM-VRSN

Registrar WHOIS Server: whois.regtime.net
Registrar URL: http://www.webnames.ru

Updated Date: 2016-10-04T08:21:57Z
Creation Date: 2016-09-28T00:00:00Z

Registrar Registration Expiration Date: 2018-09-03T04:00:00Z
Registrar: REGTIME LTD.
Registrar IANA ID: 1362
Registrar Abuse Contact
Registrar Abuse Contact Phone: +7.8463733047

Domain Status: OK
Registry Registrant ID:
Registrant Name: Legato LLC
Registrant Organization: Legato LLC
Registrant Street: Lesnaya 23, korpus 49
Registrant City: Samara
Registrant State/Province: Samara
Registrant Postal Code: 443110
Registrant Country: RU
Registrant Phone: +7.8463799039
Registrant Email: reg@legato.name

Admin Name: Legato LLC
Admin Organization: Legato LLC
Admin Street: Lesnaya 23, korpus 49
Admin City: Samara
Admin State/Province: Samara
Admin Postal Code: 443110
Admin Country: RU
Admin Phone: +7.8463799039
Admin Email: reg@legato.name

Tech Name: Legato LLC
Tech Organization: Legato LLC
Tech Street: Lesnaya 23, korpus 49
Tech City: Samara
Tech State/Province: Samara
Tech Postal Code: 443110
Tech Country: RU
Tech Phone: +7.8463799039
Tech Email: reg@legato.name

DNSSEC: Unsigned
URL of the ICANN WHOIS Data Problem Reporting System:
Last update of WHOIS database: 2017-08-14T04:15:48Z <<<
Network Whois record

Queried whois.ripe.net with "-B 195.154.43.60"…

% Information related to '195.154.0.0 – 195.154.127.255'

% Abuse contact for '195.154.0.0 – 195.154.127.255' is 'abuse@online.net'

inetnum: 195.154.0.0 – 195.154.127.255
org: ORG-ONLI1-RIPE
netname: FR-ILIAD-ENTREPRISES-CUSTOMERS
descr: Iliad Entreprises Customers
country: FR
admin-c: IENT-RIPE
tech-c: IENT-RIPE
status: LIR-PARTITIONED PA
mnt-by: MNT-TISCALIFR-B2B
created: 2012-11-02T15:33:53Z
last-modified: 2016-02-22T16:26:52Z
source: RIPE

organisation: ORG-ONLI1-RIPE
abuse-mailbox: abuse@online.net
mnt-ref: MNT-TISCALIFR-B2B
org-name: ONLINE SAS
org-type: OTHER
address: 8 rue de la ville l'eveque 75008 PARIS
e-mail: noc+ripe@as12876.net
abuse-c: AR32851-RIPE
mnt-ref: ONLINESAS-MNT
mnt-by: ONLINESAS-MNT
created: 2015-07-10T15:20:41Z
last-modified: 2016-02-23T16:20:42Z
source: RIPE

role: Iliad Entreprises Admin and Tech Contact
remarks: Iliad Entreprises is an hosting and services provider
address: 8, rue de la ville l'eveque
address: 75008 Paris
address: France
phone: +33 1 73 50 20 00
fax-no: +33 1 73 50 29 01
e-mail: ripe@online.net
notify: ripe@online.net
abuse-mailbox: abuse@online.net
tech-c: NLI-RIPE
nic-hdl: IENT-RIPE
mnt-by: ONLINE-NET-MNT
created: 2012-10-25T13:21:59Z
last-modified: 2016-02-23T11:42:21Z
source: RIPE

% Information related to '195.154.0.0/16AS12876'

route: 195.154.0.0/16
descr: Online SAS
descr: Paris, France
origin: AS12876
mnt-by: MNT-TISCALIFR
created: 2013-08-02T09:05:22Z
last-modified: 2013-08-02T09:05:22Z
source: RIPE

% This query was served by the RIPE Database Query Service version 1.89.2 (HEREFORD)
DNS records

name class type data time to live
http://www.mycanadianpharmacyrx.com IN A 195.154.43.60 3600s (01:00:00)
http://www.mycanadianpharmacyrx.com IN A 163.172.111.210 3600s (01:00:00)
mycanadianpharmacyrx.com IN TXT v=spf1 ip4:163.172.111.210 a mx ~all 3600s (01:00:00)
mycanadianpharmacyrx.com IN SOA
server: foxtorjabber.com
email: root@example.com
serial: 2017061423
refresh: 10800
retry: 3600
expire: 604800
minimum ttl: 86400
3600s (01:00:00)
mycanadianpharmacyrx.com IN NS ns1.mycanadianpharmacyrx.com 3600s (01:00:00)
mycanadianpharmacyrx.com IN NS ns2.mycanadianpharmacyrx.com 3600s (01:00:00)
mycanadianpharmacyrx.com IN MX
preference: 10
exchange: mail.mycanadianpharmacyrx.com
3600s (01:00:00)
mycanadianpharmacyrx.com IN MX
preference: 20
exchange: mail.mycanadianpharmacyrx.com
3600s (01:00:00)
mycanadianpharmacyrx.com IN A 163.172.111.210 3600s (01:00:00)
mycanadianpharmacyrx.com IN A 195.154.43.60 3600s (01:00:00)
60.43.154.195.in-addr.arpa IN PTR 195-154-43-60.rev.poneytelecom.eu 86400s (1.00:00:00)
43.154.195.in-addr.arpa IN SOA
server: nsa.online.net
email: dnsmaster@te-dns.net
serial: 2017081101
refresh: 28800
retry: 7200
expire: 604800
minimum ttl: 86400
86400s (1.00:00:00)
43.154.195.in-addr.arpa IN NS nsa.online.net 86400s (1.00:00:00)
43.154.195.in-addr.arpa IN NS nsb.online.net 86400s (1.00:00:00)
— end —
URL for this output | return to CentralOps.net, a service of Hexillion

mycanadianpharmacyrx.com
medsoffers.net
luckybestsupply.com
mydrugsservices.com
mydrugsservices.com
remedialrxmart.com
rxcanada4less.com
devoutpaint.com
shorttangy.com
ownequate.com
hugeduring.com
finestslip.com
scoreput.com
bestcaredeal.su
bestglobalassist.su
bestpillsmart.su
cqrannml.su
curativepillmart.su
curingfirstsale.su
curingrxelement.su
fastdrugeshop.su
fastfirstquality.su
fastpillseshop.su
fasttrustedshop.su
firstbestquality.su
bestwebtrade.su
flymsale.su
flynsale.su
flypsale.su
freshwebshop.su
healthdirect.su
mystocksale.su
catchtell.ru
casesecond.ru
wordbegan.ru
palatetell.ru
yardpull.ru
linehow.ru
steadwide.ru
secondhuge.ru
circleshoe.ru
lifewealth.ru
rollhouse.ru
heavybe.ru
croplowly.ru
runspeed.ru
goodmajor.ru
leadfamous.ru
daringthree.ru
alivethink.ru
huntchaste.ru
tieback.ru
lostshell.ru
yeshour.ru
toogroup.ru
helpobject.ru
figtoo.ru
shellmind.ru
creamytangy.ru
fruitfigure.ru
fruitcloud.ru
ranunique.ru
hatloving.ru
serenefriend.ru
hurryso.ru
appearhome.ru
winghope.ru
birdfor.ru
longdevout.ru
overselect.ru
whilemeek.ru
voiceride.ru
devoutslip.ru
rockraise.ru
dressnew.ru
downpearl.ru
sliptrue.ru
onlysubtle.ru
offerpound.ru
prefersudden.ru
speechsettle.ru
spreadfrom.ru
mustpress.ru
cottonsingle.ru
liftstar.ru
behindlarge.ru
littleliquid.ru
cellpush.ru
ropesoft.ru
iscase.ru
palatethey.ru
poserather.ru
seemlystring.ru
mosttall.ru
starcent.ru
finalideal.ru
tradecreate.ru
wishseat.ru
nameleave.ru
soilas.ru
spicydepend.ru
drinkpoem.ru
givinglaugh.ru
magnetalert.ru
placehard.ru
spicespruce.ru
chordgame.ru
mightyhow.ru
tallwhose.ru
mixtruck.ru
duckquick.ru
exactbeats.ru
juicyanimal.ru
landcreamy.ru
leasttoward.ru
weightover.ru
treebits.ru
fourcrowd.ru
birdpaper.ru
lotvary.ru
frontmiddle.ru
beginand.ru
finishhim.ru
driveold.ru
exoticdo.ru
soilactive.ru
northapple.ru
figtell.ru
searchagree.ru
centersuperb.ru
piousdivine.ru
colonyrow.ru
singlebut.ru
pairlaugh.ru
iflarge.ru
dropdreamy.ru
tastysmile.ru
trustneed.ru
endbottom.ru
waitthem.ru
neckrose.ru
losthe.ru
marketplane.ru
onceagain.ru
zoomwealth.ru
sittube.ru
suffixlittle.ru
inventuse.ru
drawmunchy.ru
sontender.com
lostwhy.com
dearspoke.com
answeryard.com
sweetslick.com
boughtstream.com
zipchords.com
eitherzest.com
skinsalt.com
plumform.com
helpsweet.com
gavegame.com
fruitear.com
newlucksale.su
prowebstore.su
stocksaleweb.su
targetvipweb.su
bestdirect.su
bestmhit.su
bestmystock.su
bestnhit.su
bestphit.su
bestwebmarket.su
directmylife.su
eventsaleweb.su
freshastock.su
freshmsale.su
bestdirect.su
bestmhit.su
bestmystock.su
bestnhit.su
bestphit.su
bestwebmarket.su
directmylife.su
eventsaleweb.su
freshastock.su
freshmsale.su
freshnsale.su
freshpsale.su
givehota.su
givehotb.su
givehotc.su
goodtarget.su
hotmyservice.su
hotordersale.su
hottargetweb.su
magichit.su
magicnsale.su
magicpsale.su
magicvipsale.su
myhotclaim.su
otherwebm.su
otherwebn.su
otherwebp.su
saledirectn.su
stablewebz.su
startluck.su
supportwebp.su
targetsale.su
topwinorder.su
tradensale.su
tradewebsale.su
webdesigne.su
websaledirect.su
westsalemarket.su
genericherbmall.su
gooddrugcompany.su
goodremedystore.su
healingrxreward.su
homefastassist.su
hotaidstore.su
hotpillprogram.su
ixmubgxs.su
kuzuipck.su
luckytabsbargain.su
magicaidquality.su
magicmedsoutlet.su
mybestelement.su
myhotbargain.su
myonlineshop.su
newpillservices.su
organicmedsgroup.su
perfectrxmarket.su
pureherbssale.su
qrgedywj.su
safesmartquality.su
theherbalvalue.su
theherbelement.su
yourpharmreward.su
ztbnuprh.su
bestherbcompany.ru
bestpilleshop.ru
canadiancareshop.ru
curingpillsshop.ru
excellentaiddeal.ru
fasttabsprogram.ru
firstdrugsdeal.ru
firsthotgroup.ru
firstmedseshop.ru
firstpillreward.ru
genericmedsinc.ru
genericpillmall.ru
genericsafedeal.ru
gilbertinarosetta.ru
goodfastmarket.ru
goodfirstelement.ru
goodprivategroup.ru
goodrxoutlet.ru
healingrxvalue.ru
healingsafeeshop.ru
herbaldrugmart.ru
homemedsvalue.ru
homesmartwebmart.ru
hotdrugprogram.ru
hotgenericsshop.ru
hotherbaldeal.ru
hotherbaleshop.ru
hotherbshop.ru
hotpharmreward.ru
hotrxreward.ru
hottabsshop.ru
indiraophelia.ru
linetmelisandra.ru
luckydrugquality.ru
luckyremedytrade.ru
luckysmartstore.ru
luckytabletshop.ru
maddyaniakaty.ru
madelinamegnari.ru
magicmedicalshop.ru
magicsecurevalue.ru
magicsmartassist.ru
magictrustedmart.ru
maurinejenlilly.ru
medicalaidmart.ru
medicaldrugsmart.ru
midgetasia.ru
mirelledusty.ru
mobleuwp.ru
mycaremall.ru
mymedicaregroup.ru
mypillmall.ru
myprivatedeal.ru
nedalaraemyle.ru
nerissaminni.ru
newmedssupply.ru
neworganicstore.ru
newremedialeshop.ru
newremedyeshop.ru
newsecurestore.ru
onlinefirsttrade.ru
onlinerxprogram.ru
organicaidvalue.ru
organicpillsshop.ru
privatefastvalue.ru
privatefirstshop.ru
privatesmartshop.ru
puredrugsdeal.ru
purefastservices.ru
puregenericssale.ru
pureherbmart.ru
purepillseshop.ru
pureprivatemall.ru
pureprivatemart.ru
purerxbargain.ru
purerxmart.ru
remedialcaredeal.ru
remedialmedsinc.ru
safedrugseshop.ru
safehealthmarket.ru
saferemedialmart.ru
securecareshop.ru
smartherbalmart.ru
smartherbssupply.ru
smarthotmarket.ru
smartmedssupply.ru
smartrxgroup.ru
smartrxmall.ru
sopheyainsley.ru
thecurativeeshop.ru
thecurativevalue.ru
thehottrade.ru
themedssale.ru
thenaturaloutlet.ru
thepillreward.ru
therxassist.ru
thetabsmarket.ru
youraidwebmart.ru
yourgenericsmall.ru
yourgenericsshop.ru
yourherbsmart.ru
youronlineoutlet.ru
yourorganicmall.ru
yoursmartreward.ru
catchtell.ru
casesecond.ru
wordbegan.ru
palatetell.ru
yardpull.ru
linehow.ru
steadwide.ru
secondhuge.ru
circleshoe.ru
lifewealth.ru
rollhouse.ru
heavybe.ru
croplowly.ru
runspeed.ru
goodmajor.ru
leadfamous.ru
daringthree.ru
alivethink.ru
huntchaste.ru
tieback.ru
lostshell.ru
yeshour.ru
toogroup.ru
helpobject.ru
figtoo.ru
shellmind.ru
creamytangy.ru
fruitfigure.ru
fruitcloud.ru
ranunique.ru
hatloving.ru
serenefriend.ru
hurryso.ru
appearhome.ru
winghope.ru
birdfor.ru
longdevout.ru
overselect.ru
whilemeek.ru
voiceride.ru
devoutslip.ru
rockraise.ru
dressnew.ru
downpearl.ru
sliptrue.ru
onlysubtle.ru
offerpound.ru
prefersudden.ru
speechsettle.ru
spreadfrom.ru
mustpress.ru
cottonsingle.ru
liftstar.ru
behindlarge.ru
littleliquid.ru
cellpush.ru
ropesoft.ru
iscase.ru
palatethey.ru
poserather.ru
seemlystring.ru
mosttall.ru
starcent.ru
finalideal.ru
tradecreate.ru
wishseat.ru
nameleave.ru
soilas.ru
spicydepend.ru
drinkpoem.ru
givinglaugh.ru
magnetalert.ru
placehard.ru
spicespruce.ru
chordgame.ru
mightyhow.ru
tallwhose.ru
mixtruck.ru
duckquick.ru
exactbeats.ru
juicyanimal.ru
landcreamy.ru
leasttoward.ru
weightover.ru
treebits.ru
fourcrowd.ru
birdpaper.ru
lotvary.ru
frontmiddle.ru
beginand.ru
finishhim.ru
driveold.ru
exoticdo.ru
soilactive.ru
northapple.ru
figtell.ru
searchagree.ru
centersuperb.ru
piousdivine.ru
colonyrow.ru
singlebut.ru
pairlaugh.ru
iflarge.ru
dropdreamy.ru
tastysmile.ru
trustneed.ru
endbottom.ru
waitthem.ru
neckrose.ru
losthe.ru
marketplane.ru
onceagain.ru
zoomwealth.ru
sittube.ru
suffixlittle.ru
inventuse.ru
drawmunchy.ru
sontender.com
lostwhy.com
dearspoke.com
answeryard.com
sweetslick.com
boughtstream.com
zipchords.com
eitherzest.com
skinsalt.com
plumform.com
helpsweet.com
gavegame.com
fruitear.com
onlinepharmacygot.com
activeplum.ru
alwayswhich.ru
appearabove.ru
arrivethere.ru
beold.ru
bluepaper.ru
carebottom.ru
chancejob.ru
circleplanet.ru
citypower.ru
closebefore.ru
colonyready.ru
countrise.ru
dimpleif.ru
duckour.ru
eitherwealth.ru
eventseven.ru
everegg.ru
eyemount.ru
facebought.ru
factwent.ru
fairyes.ru
feelat.ru
findhardy.ru
fineclear.ru
giftedcorner.ru
gifteddirect.ru
guessflower.ru
heatfact.ru
himspeed.ru
ifdrool.ru
jewelswim.ru
joinspace.ru
knowwhile.ru
legacybeat.ru
lengthwant.ru
lightscores.ru
maxistream.ru
mixrail.ru
northsame.ru
oceanmade.ru
outfollow.ru
palatedollar.ru
passnine.ru
peopleexact.ru
picklong.ru
planettheir.ru
potentrange.ru
rootfig.ru
rosynext.ru
sharpnight.ru
someown.ru
standcreate.ru
storyhurry.ru
suffixfun.ru
twosheet.ru
vanishperiod.ru
whizthere.ru
wishroot.ru
yulepitch.ru
zoomfeed.ru
yourrxquality.com
safemedsquality.com
bathshebakarrie.ru
bestdruggroup.ru
brettsasha.ru
chrystalnannette.ru
dinaaurora.ru
gertiejody.ru
globalherbsgroup.ru
herbaltabseshop.ru
hotdrugsoutlet.ru
kellyjamie.ru
kessiahilka.ru
lettijazmin.ru
liesaleena.ru
luckymedsgroup.ru
mehetabeljyoti.ru
ofeliastefania.ru
purehealingtrade.ru
saudraimojean.ru
winnifredleola.ru
yourorganiceshop.ru
yourpillseshop.ru
luckybestsupply.com
magicsecuresale.com
remedialrxmart.com
freshpweb.su
goodzmaster.su
gopuoknj.masterfsale.su
magicmsale.su
magicnsale.su
masterfsale.su
mastergsale.su
masterhsale.su
vfee.wemamaster.su
wemamaster.su
wemcmaster.su
wqiovr.masterfsale.su
yeiinijce.magicmsale.su
bestglobalmall.su
bestonlinesale.su
bestonlinevalue.su
bestpharmelement.su
globalpillsupply.su
goodherbsreward.su
goodpillscompany.su
goodpillsstore.su
herbalsecuremart.su
herbalsecureshop.su
homefirstelement.su
homepharmacymall.su
hometabletvalue.su
hottabletprogram.su
magicherbprogram.su
medicaldrugmall.su
medicaldrugsmall.su
mybiologicalshop.su
myherbsprogram.su
naturalrxquality.su
onlinesafegroup.su
privatehealthinc.su
privatepillshop.su
puremedsgroup.su
safefirstgroup.su
safegenericsdeal.su
safeherbsupply.su
smartbesteshop.su
thedrugsbargain.su
thefastservice.su
trusteddrugvalue.su
abigailloraine.ru
adalinedasya.ru
bestbestprogram.ru
bestdruggroup.ru
bestglobalassist.ru
brandiefancie.ru
ceceliaritakandy.ru
celinenicolle.ru
chrystalnannette.ru
curingfirstgroup.ru
dbqsktxy.ru
deloriaromy.ru
esmabilliinga.ru
firstnaturalsale.ru
firstpharmmarket.ru
friedakimmie.ru
friederikeemilia.ru
gertiejody.ru
globalherbsgroup.ru
goodpharmcompany.ru
goodtrustedvalue.ru
healingdrugsdeal.ru
herbalfirstmall.ru
homehotshop.ru
homeprivategroup.ru
homeprivategroup.ru
hotcanadiangroup.ru
hotdrugsoutlet.ru
hotherbsprogram.ru
imogeneelysee.ru
janeleddie.ru
joleepamelina.ru
kellyjamie.ru
lilydanyakass.ru
luckygenericdeal.ru
luckymedsgroup.ru
magicdrugsoutlet.ru
medicalfirstinc.ru
mehetabeljyoti.ru
myfastinvestment.ru
mymedssale.ru
onlineaidsupply.ru
pegeensheilakathryn.ru
philomenakassandra.ru
puresafeinc.ru
rainamarcela.ru
ralinajordain.ru
raniquejanenna.ru
rhiannabridie.ru
safesafedeal.ru
safesafequality.ru
saudraimojean.ru
securetabsmarket.ru
sileasberetadda.ru
smartrxoutlet.ru
themedicalsupply.ru
theorganicvalue.ru
trustedrxsale.ru
yourorganiceshop.ru
yourpillseshop.ru
fasttablettrade.com
safemedsquality.com
yourrxquality.com
adoreejuli.trade
bobinettelauraine.win
cassondramarianne.trade
christinaula.win
doralynnerasia.trade
eleonoreelga.trade
elladinenedi.trade
familycaregroup.win
gabybobine.win
giannawandie.win
giuliababb.trade
hediblake.win
helenaelwira.win
hollyannecamila.win
homehealthshop.win
honorlorettalorna.trade
hotherbssale.win
hotpillassist.trade
jackiseline.win
jessicaaime.trade
jobynababs.trade
karrieshauna.trade
kaylamegan.win
kylieluce.win
lidacindy.win
lilllieselie.trade
linnelllynelle.trade
luckyfarand.win
lulitadanyette.win
lusacorry.win
maybellemaryjane.win
melonyelayne.win
mercieroobbie.trade
mercipatsy.trade
morissaainsley.trade
mysafegroup.trade
mytrustedoutlet.win
naneteodelia.trade
nelllonee.win
oraliemarjy.trade
pennymorganica.win
riannondosi.trade
ronicapearle.win
roryaurea.win
sashareina.trade
sellejoeann.trade
susiemyrah.win
suzannloria.win
tabbirosemary.trade
terascarlett.trade
yourhotdeal.trade
abagailemmeline.eu
alisamargarette.eu
amitammara.eu
andrianajankaivie.eu
charilhelli.eu
clarykacey.eu
curingherbinc.eu
danigenevra.eu
eadiesuzanna.eu
elnorelynemma.eu
fannygayla.eu
gustaalbina.eu
herbalpillsinc.eu
ingridrebeangel.eu
karmenmarcia.eu
katharynjune.eu
katharynwinne.eu
kathymarylou.be
kimberleejobye.eu
leelagabbey.eu
leilajanaya.eu
lilashelaine.eu
lurettelatia.eu
lydienicoli.eu
luckybestsupply.com
mydrugsservices.com
mydrugsservices.com
remedialrxmart.com
maxyfaydravan.eu
moinajuliet.eu
nataleegabey.eu
nathaliemerna.eu
neillecloe.eu
nellievivien.be
organicrxmarket.eu
purepharmprogram.eu
puresecuregroup.eu
ralinaelsi.eu
ruthjaimie.eu
saschajennine.eu
sashalinzyavis.eu
scarleteva.eu
shannakellina.eu
shirleejoana.eu
siouxieaimil.eu
tabbiecybilivie.eu
qxqapd.topmweb.su
yetagenfzi.toplweb.su
topnweb.su
topmweb.su
toplweb.su
trustedsafemart.eu
vannierochell.be
vivisilvana.eu
wenonamarji.eu
aliceahaley.be
anyaimogene.be
chereannabal.be
coraliechelsie.be
dorelisetta.be
florellamadlen.be
hildegardedottie.eu
hotgenericvalue.be
jocelinjolyalene.eu
katerinamarabel.eu
kaylaalysia.eu
lissamatelda.be
mabelleemmi.be
rebbeccakara.eu
ronnirosella.be
shannaolivette.be
sybilaferdinanda.be
thehealingmart.eu

WhoIs safemedsquality.com

Leave a comment

Drug Enforcement Agency

United States of America

The Ryan Haight Act Known as
Online Pharmacy Consumer Protection Act of 2008
Sec. 2. Requirement of a valid prescription for
controlled substances dispensed by means of the Internet.

Who’s Behind These Online Pharmacies

SUMMARY: The Ryan Haight Online Pharmacy Consumer Protection Act,
which was enacted on October 15, 2008,amended the Controlled Substances Act and Controlled Substances Import and Export Act by adding several new provisions to prevent the illegal distribution and dispensing of controlled substances by means of the Internet.
_________________________________

Address lookup

canonical name:safemedsquality.com
aliases
addresses :78.107.252.174
Domain Whois record

Queried whois.internic.net with “dom safemedsquality.com”…

Domain Name: SAFEMEDSQUALITY.COM
Registry Domain ID: 2146893551_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.tucows.com
Registrar URL: http://www.tucowsdomains.com
Updated Date: 2017-07-26T15:32:02Z
Creation Date: 2017-07-25T19:45:41Z
Registry Expiry Date: 2018-07-25T19:45:41Z
Registrar: Tucows Domains Inc.
Registrar IANA ID: 69
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: ok

Name Server: NS1.SAFEMEDSQUALITY.COM
Name Server: NS2.SAFEMEDSQUALITY.COM

DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form:

Last update of whois database: 2017-08-15T16:36:59Z

Queried whois.tucows.com with “safemedsquality.com”…

Domain Name: SAFEMEDSQUALITY.COM
Domain ID: 2146893551_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.tucows.com
Registrar URL: http://tucowsdomains.com
Updated Date: 2017-08-10T17:52:23Z
Creation Date: 2017-07-25T19:45:41Z
Registrar Registration Expiration Date: 2018-07-25T19:45:41Z
Registrar: TUCOWS, INC.
Registrar IANA ID: 69
Registrar Abuse Contact Email: d
Registrar Abuse Contact Phone: +1.4165350123
Domain Status: ok

Registry Registrant ID:
Registrant Name: Contact Commercial Limited
Registrant Organization: Contact Commercial Limited
Registrant Street: 68 Windsor Road
Registrant City: Swindon
Registrant State/Province: Swindon
Registrant Postal Code: SN3 1JX
Registrant Country: GB
Registrant Phone: +44.2035145961
Registrant Email: whois@contactprivacyprotect.com

Registry Admin ID:
Admin Name: Contact Commercial Limited
Admin Organization: Contact Commercial Limited
Admin Street: 68 Windsor Road
Admin City: Swindon
Admin State/Province: Swindon
Admin Postal Code: SN3 1JX
Admin Country: GB
Admin Phone: +44.2035145961
Admin Email: whois@contactprivacyprotect.com

Registry Tech ID:
Tech Name: Contact Commercial Limited
Tech Organization: Contact Commercial Limited
Tech Street: 68 Windsor Road
Tech City: Swindon
Tech State/Province: Swindon
Tech Postal Code: SN3 1JX
Tech Country: GB
Tech Phone: +44.2035145961
Tech Email: whois@contactprivacyprotect.com

Name Server: NS1.SAFEMEDSQUALITY.COM
Name Server: NS2.SAFEMEDSQUALITY.COM
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System:

Last update of WHOIS database: 2017-08-10T17:52:23Z
Network Whois record

Queried whois.ripe.net with “-B 78.107.252.174″…
Information related to ‘78.107.248.0 – 78.107.255.255’
Abuse contact for ‘78.107.248.0 – 78.107.255.255’ is ‘abuse@beeline.ru’

inetnum: 78.107.248.0 – 78.107.255.255
netname: CORBINA-BROADBAND-STATIC
descr: Static IP pool for broadband customers in Moscow
country: RU
admin-c: CORB1-RIPE
tech-c: CORB1-RIPE
status: ASSIGNED PA
mnt-by: RU-CORBINA-MNT
mnt-lower: RU-CORBINA-MNT
mnt-routes: RU-CORBINA-MNT
created: 2008-01-23T14:46:37Z
last-modified: 2008-01-23T14:46:37Z
source: RIPE

role: CORBINA TELECOM Network Operations
address: CORBINA TELECOM/Internet Network Operations
address: Kozhevnicheskij proezd, 1
address: Moscow, Russia
address: 115114
phone: +7 495 755 5648
fax-no: +7 495 787 1990
e-mail: internet@b2b.beeline.ru
remarks: ———————————————————–
remarks: Feel free to contact Corbina Telecom NOC to
remarks: resolve networking problems related to Corbina
remarks: ———————————————————–
remarks: User support, general questions: support@corbina.net
remarks: Routing, peering, security: ipnoc@corbina.net
remarks: Report spam and abuse: abuse@beeline.ru
remarks: Mail and news: postmaster@corbina.net
remarks: DNS: hostmaster@corbina.net
remarks: ———————————————————–
admin-c: AK644-RIPE
tech-c: MCS91-RIPE
nic-hdl: CORB1-RIPE
mnt-by: RU-CORBINA-MNT
abuse-mailbox: abuse@beeline.ru
created: 1970-01-01T00:00:00Z
last-modified: 2016-02-16T09:47:15Z
source: RIPE

% Information related to ‘78.106.0.0/15AS8402’

route: 78.106.0.0/15
descr: RU-CORBINA BLOCK #7
origin: AS8402
mnt-by: RU-CORBINA-MNT
notify: noc@corbina.net
created: 2007-06-07T06:36:18Z
last-modified: 2007-06-07T06:36:18Z
source: RIPE

% This query was served by the RIPE Database Query Service version 1.89.2 (HEREFORD)
DNS records

name class type data time to live
safemedsquality.com IN A 78.107.252.174 598s (00:09:58)
174.252.107.78.in-addr.arpa IN PTR 0891021126.static.corbina.ru 10800s (03:00:00)
252.107.78.in-addr.arpa IN SOA
server: dns1.corbina.net
email: hostmaster@corbina.net
serial: 1502725321
refresh: 3600
retry: 300
expire: 604800
minimum ttl: 3600
10800s (03:00:00)
252.107.78.in-addr.arpa IN NS dns2.corbina.net 10800s (03:00:00)
252.107.78.in-addr.arpa IN NS dns1.corbina.net 10800s (03:00:00)
— end —
URL for this output | return to CentralOps.net,